226 related articles for article (PubMed ID: 35307993)
1. "Drug-Carrier" Synergy Therapy for Amyloid-β Clearance and Inhibition of Tau Phosphorylation via Biomimetic Lipid Nanocomposite Assembly.
Han G; Bai K; Yang X; Sun C; Ji Y; Zhou J; Zhang H; Ding Y
Adv Sci (Weinh); 2022 May; 9(14):e2106072. PubMed ID: 35307993
[TBL] [Abstract][Full Text] [Related]
2. Tau-Targeted Multifunctional Nanocomposite for Combinational Therapy of Alzheimer's Disease.
Chen Q; Du Y; Zhang K; Liang Z; Li J; Yu H; Ren R; Feng J; Jin Z; Li F; Sun J; Zhou M; He Q; Sun X; Zhang H; Tian M; Ling D
ACS Nano; 2018 Feb; 12(2):1321-1338. PubMed ID: 29364648
[TBL] [Abstract][Full Text] [Related]
3. Methylene Blue Inhibits Formation of Tau Fibrils but not of Granular Tau Oligomers: A Plausible Key to Understanding Failure of a Clinical Trial for Alzheimer's Disease.
Soeda Y; Saito M; Maeda S; Ishida K; Nakamura A; Kojima S; Takashima A
J Alzheimers Dis; 2019; 68(4):1677-1686. PubMed ID: 30909223
[TBL] [Abstract][Full Text] [Related]
4. Customized Intranasal Hydrogel Delivering Methylene Blue Ameliorates Cognitive Dysfunction against Alzheimer's Disease.
Liu Y; Tan Y; Cheng G; Ni Y; Xie A; Zhu X; Yin C; Zhang Y; Chen T
Adv Mater; 2024 May; 36(19):e2307081. PubMed ID: 38395039
[TBL] [Abstract][Full Text] [Related]
5. Ultrasound with microbubbles improves memory, ameliorates pathology and modulates hippocampal proteomic changes in a triple transgenic mouse model of Alzheimer's disease.
Shen Y; Hua L; Yeh CK; Shen L; Ying M; Zhang Z; Liu G; Li S; Chen S; Chen X; Yang X
Theranostics; 2020; 10(25):11794-11819. PubMed ID: 33052247
[TBL] [Abstract][Full Text] [Related]
6. Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.
Xin SH; Tan L; Cao X; Yu JT; Tan L
Neurotox Res; 2018 Oct; 34(3):733-748. PubMed ID: 29626319
[TBL] [Abstract][Full Text] [Related]
7. Interaction between Aβ and Tau in the Pathogenesis of Alzheimer's Disease.
Zhang H; Wei W; Zhao M; Ma L; Jiang X; Pei H; Cao Y; Li H
Int J Biol Sci; 2021; 17(9):2181-2192. PubMed ID: 34239348
[TBL] [Abstract][Full Text] [Related]
8. Dimeric amyloid beta protein rapidly accumulates in lipid rafts followed by apolipoprotein E and phosphorylated tau accumulation in the Tg2576 mouse model of Alzheimer's disease.
Kawarabayashi T; Shoji M; Younkin LH; Wen-Lang L; Dickson DW; Murakami T; Matsubara E; Abe K; Ashe KH; Younkin SG
J Neurosci; 2004 Apr; 24(15):3801-9. PubMed ID: 15084661
[TBL] [Abstract][Full Text] [Related]
9. Methylene blue reduces aβ levels and rescues early cognitive deficit by increasing proteasome activity.
Medina DX; Caccamo A; Oddo S
Brain Pathol; 2011 Mar; 21(2):140-9. PubMed ID: 20731659
[TBL] [Abstract][Full Text] [Related]
10. Optimized liposomes with transactivator of transcription peptide and anti-apoptotic drugs to target hippocampal neurons and prevent tau-hyperphosphorylated neurodegeneration.
Kuo YC; Chen CL; Rajesh R
Acta Biomater; 2019 Mar; 87():207-222. PubMed ID: 30716553
[TBL] [Abstract][Full Text] [Related]
11. Effects of CX3CR1 and Fractalkine Chemokines in Amyloid Beta Clearance and p-Tau Accumulation in Alzheimer's Disease (AD) Rodent Models: Is Fractalkine a Systemic Biomarker for AD?
Merino JJ; Muñetón-Gómez V; Alvárez MI; Toledano-Díaz A
Curr Alzheimer Res; 2016; 13(4):403-12. PubMed ID: 26567742
[TBL] [Abstract][Full Text] [Related]
12. Methylene Blue Improves Brain Mitochondrial ABAD Functions and Decreases Aβ in a Neuroinflammatory Alzheimer's Disease Mouse Model.
Zakaria A; Hamdi N; Abdel-Kader RM
Mol Neurobiol; 2016 Mar; 53(2):1220-1228. PubMed ID: 25601181
[TBL] [Abstract][Full Text] [Related]
13. Abnormal interaction of VDAC1 with amyloid beta and phosphorylated tau causes mitochondrial dysfunction in Alzheimer's disease.
Manczak M; Reddy PH
Hum Mol Genet; 2012 Dec; 21(23):5131-46. PubMed ID: 22926141
[TBL] [Abstract][Full Text] [Related]
14. Key Peptides and Proteins in Alzheimer's Disease.
Penke B; Bogár F; Paragi G; Gera J; Fülöp L
Curr Protein Pept Sci; 2019; 20(6):577-599. PubMed ID: 30605056
[TBL] [Abstract][Full Text] [Related]
15. Amyloid Beta and Phosphorylated Tau-Induced Defective Autophagy and Mitophagy in Alzheimer's Disease.
Reddy PH; Oliver DM
Cells; 2019 May; 8(5):. PubMed ID: 31121890
[TBL] [Abstract][Full Text] [Related]
16. Increased tauopathy drives microglia-mediated clearance of beta-amyloid.
Chen W; Abud EA; Yeung ST; Lakatos A; Nassi T; Wang J; Blum D; Buée L; Poon WW; Blurton-Jones M
Acta Neuropathol Commun; 2016 Jun; 4(1):63. PubMed ID: 27339073
[TBL] [Abstract][Full Text] [Related]
17. Attenuation of synaptic toxicity and MARK4/PAR1-mediated Tau phosphorylation by methylene blue for Alzheimer's disease treatment.
Sun W; Lee S; Huang X; Liu S; Inayathullah M; Kim KM; Tang H; Ashford JW; Rajadas J
Sci Rep; 2016 Oct; 6():34784. PubMed ID: 27708431
[TBL] [Abstract][Full Text] [Related]
18. Abeta and tau form soluble complexes that may promote self aggregation of both into the insoluble forms observed in Alzheimer's disease.
Guo JP; Arai T; Miklossy J; McGeer PL
Proc Natl Acad Sci U S A; 2006 Feb; 103(6):1953-8. PubMed ID: 16446437
[TBL] [Abstract][Full Text] [Related]
19. Screening of treatment targets for Alzheimer's disease from the molecular mechanisms of impairment by β-amyloid aggregation and tau hyperphosphorylation.
Lin LF; Luo HM
Neurosci Bull; 2011 Feb; 27(1):53-60. PubMed ID: 21270904
[TBL] [Abstract][Full Text] [Related]
20. Soluble Conformers of Aβ and Tau Alter Selective Proteins Governing Axonal Transport.
Sherman MA; LaCroix M; Amar F; Larson ME; Forster C; Aguzzi A; Bennett DA; Ramsden M; Lesné SE
J Neurosci; 2016 Sep; 36(37):9647-58. PubMed ID: 27629715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
